Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis

Pharmacotherapy

Volumn 31, Issue 2, 2011, Pages 146-157

  Berlana, David ^a   Llop, Josep Manel ^a   Manresa, Frederic ^a   Jódar, Ramón ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Bronchiectasis; Chronic obstructive pulmonary disease; Colistin; COPD; Inhaled antibiotics; Pseudomonas aeruginosa; Tobramycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLISTIN; CORTICOSTEROID; MACROLIDE; QUINOLONE; THEOPHYLLINE; TOBRAGOBENS; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADULT; AIRWAY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BRONCHITIS; BRONCHUS; CAUCASIAN; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG SAFETY; ERADICATION THERAPY; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; OUTPATIENT CARE; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RESPIRATORY FUNCTION; TREATMENT DURATION; UNIVERSITY HOSPITAL;

ADMINISTRATION, INHALATION; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; BRONCHITIS, CHRONIC; COLISTIN; CYSTIC FIBROSIS; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 79551605256     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.2.146     Document Type: Article

References (59)

1. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2-year follow up study. Thorax 2004;59:387-95. (Pubitemid 38624744)
2. Miravitlles M, Murio C, Guerrero T, Gisbert R, for the DAFNE Study Group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002;121:1449-55. (Pubitemid 34499654)
3. Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Respir Med 2004;98:99-107. (Pubitemid 38181126)
4. Chang AB, Bilton D. Exacerbations in cystic fibrosis: 4. Noncystic fibrosis bronchiectasis.Thorax 2008;63:269-76.
5. O'Donnell AE. Bronchiectasis. Chest 2008;134:815-23.
6. 1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:1090-5.
7. Kelly MG, Murphy S, Elborn JS. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur J Intern Med 2003;14:488-92. (Pubitemid 38210174)
8. Rosell A, Monsó E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005;165:891-7. (Pubitemid 40563235)
9. Conway SP. Nebulized antibiotic therapy: the evidence. Chron Respir Dis 2005;2:35-41.
10. Ryan G, Mukhopadhyay S, Singh M. Nebulised antipseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003;(3):CD001021.
11. Vendrell M, de Gracia J, Olveira C, et al. Diagnosis and treatment of bronchiectasis: Spanish Society of Pneumology and Thoracic Surgery [in Spanish]. Arch Bronconeumol 2008;44:629-40.
12. Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658-64.
13. Steinfort DP, Steinfort C. Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J 2007;37:495-8. (Pubitemid 46855088)
14. Drobnic ME, Sune P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39:39-44. (Pubitemid 40052376)
15. Cantón R, Cobos N, de Gracia J, et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005;11:690-703. (Pubitemid 41167334)
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83. (Pubitemid 17055592)
17. Crosbie PA, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009;33:171-81.
18. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204. (Pubitemid 17009877)
19. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008;63:831-8.
20. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
21. Murray PR, Washington JA. Microscopic and bacteriologic análisis of expectorates sputum. Mayo Clinic Proc 1975;50:339-44.
22. Sanchis J, Casan P, Castillo J, Gonzalez N, Palenciano L, Roca J. Normativa para la práctica de la espirometrúa forzada. Arch Bronconeumol 1989;25:132-42.
23. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 5th ed. NCCLS document M7-A5, vol. 20, no. 2. Villanova, PA: National Committee for Clinical Laboratory Standards, 2000.
24. National Committee for Clinical Laboratory Standards. Performance for antimicrobial susceptibility testing: 9th informational supplement. NCCLS document M100-S9. Wayne, PA: National Committee for Clinical Laboratory Standards, 1999.
25. Soussy CJ, Cluzel R, Courvalin P, et al. Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria in France. Eur J Clin Microbiol Infect Dis 1994;13:238-46.
26. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45. (Pubitemid 12149145)
27. Domenech JM. SPSS macro !NI2IS. Sample size (rate) and power determination: two independent samples [computer program]. 2009.02.19. Bellaterra: Universitat Autònoma de Barcelona; 2009. Available from http://www.metodo.uab.cat/macros.htm. Accessed March 4, 2009.
28. Keene ON, Jones MR, Lane PW, Anderson J. Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study. Pharm Stat 2007;6:89-97. (Pubitemid 46938845)
29. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:842-6.
30. Onen ZP, Gulbay BE, Sen E, et al. Analysis of the factors related to mortality in patients with bronchiectasis. Resp Med 2007;101:1390-7. (Pubitemid 46832240)
31. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34:843-9.
32. Sudfeld CR, Dasenbrook EC, Merz WG, Carroll KC, Boyle MP. Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis. J Cyst Fibros 2010;9:110-16.
33. Pihet M, Carrere J, Cimon B, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis: a review. Med Mycol 2009;47;387-97.
34. Orriols R, Roig J, Ferrer J, et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999;93:476-80. (Pubitemid 29364062)
35. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162:481-5. (Pubitemid 30647187)
36. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005;127:1420-6. (Pubitemid 46224309)
37. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92. (Pubitemid 28110583)
38. Ratjen F, Döring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001;358:983-4. (Pubitemid 32913526)
39. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-9.
40. Nikolaizik WH, Vietzke D, Ratjen F. A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients. Can Respir J 2008;15:259-62.
41. Davies G, Wells AU, Doffman S, Watanabe S, Wilson R. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J 2006;28:974-9. (Pubitemid 46331967)
42. Lobue PA. Inhaled tobramycin: not just for cystic fibrosis anymore? Chest 2005;127:1098-101.
43. Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2008;21:71-6.
44. Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 2007;132:562-8. (Pubitemid 47282389)
45. Ramsey BW, Pepe MS, Quan JM, et al, for the Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
46. Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J infect Dis 1999;179:1190-6.
47. Tré-Hardy M, Macé C, El Manssouri N, Vanderbist F, Traore H, Devleeschouwer MJ. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model. Int J Antimicrb Agents 2009;44:40-5.
48. Morosini MI, García-Castillo M, Loza E, Pérez- Vázquez M, Baquero F, Cantón R. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J Clin Microbiol 2005;43:4480-5. (Pubitemid 41298231)
49. Tsang KW, Chan WM, Ho PL, Chan K, Lam WK, Ip MS. A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis. Eur Respir J 1999;14:1206-9.
50. Moss RB. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001;120(3 suppl):S107-13.
51. Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Høiby N. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 2008;7:391-7.
52. Denton M, Kerr K, Mooney L, et al. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol 2002;34:257-61.
53. Tsang KW, Bilton D. Clinical challenges in managing bronchiectasis. Respirology 2009;14:637-50.
54. Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006;130:1503-10. (Pubitemid 44786746)
55. Hill SL, Stockley RA. Effect of short- and long-term antibiotic response on lung function in bronchiectasis. Thorax 1986;41:798-800. (Pubitemid 16020230)
56. Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003;63:2501-20. (Pubitemid 37392915)
57. Elborn JS, Henig NR. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. Expert Opin Pharmacother 2010;11:1373-85.
58. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16.
59. Garcia-Vidal C, Almagro P, Romaní V, et al. Pseudomonas aeruginosa in patients hospitalized for COPD exacerbation: a prospective study. Eur Respir J 2009;34:1072-8.